Solid Biosciences Inc. (SLDB)
NASDAQ: SLDB · Real-Time Price · USD
5.62
+0.10 (1.81%)
At close: Oct 24, 2025, 4:00 PM EDT
5.77
+0.15 (2.67%)
After-hours: Oct 24, 2025, 6:46 PM EDT
Solid Biosciences Stock Forecast
Stock Price Forecast
The 10 analysts that cover Solid Biosciences stock have a consensus rating of "Strong Buy" and an average price target of $15, which forecasts a 166.90% increase in the stock price over the next year. The lowest target is $10 and the highest is $20.
Price Target: $15 (+166.90%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Aug 14, 2025.
Analyst Ratings
The average analyst rating for Solid Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 4 | 4 | 4 |
| Buy | 7 | 6 | 6 | 6 | 6 | 6 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 10 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $15 | Strong Buy | Maintains | $15 | +166.90% | Aug 14, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $15 → $13 | Buy | Maintains | $15 → $13 | +131.32% | Aug 14, 2025 |
| Wedbush | Wedbush | Buy Maintains $17 → $14 | Buy | Maintains | $17 → $14 | +149.11% | Aug 13, 2025 |
| Citigroup | Citigroup | Strong Buy Initiates $14 | Strong Buy | Initiates | $14 | +149.11% | Jun 26, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +255.87% | Jun 17, 2025 |
Financial Forecast
Revenue This Year
255.00K
Revenue Next Year
n/a
from 255.00K
EPS This Year
-2.04
from -3.06
EPS Next Year
-1.98
from -2.04
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.2M | n/a | |||
| Avg | 255,000 | n/a | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.84 | -1.41 | |||
| Avg | -2.04 | -1.98 | |||
| Low | -2.74 | -2.63 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.